Distribution of events in pB ALL Ph− patients according to MRD classification
| . | MRD-SR . | MRD-IR . | MRD-HR . | Total . | ||||
|---|---|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | No. . | % . | No. . | % . | |
| Total | 1348 | 42.3 | 1647 | 51.7 | 189 | 5.9 | 3184 | |
| Resistant* | 0 | 0 | 3 | 1.6 | 3 | 0.1 | ||
| Relapses | 61 | 4.5 | 266 | 16.2 | 60 | 31.7 | 387 | 12.1 |
| Bone marrow | 32 | 2.4 | 168 | 10.2 | 49 | 25.9 | 249 | 7.8 |
| Central nervous system | 9 | 0.6 | 29 | 1.8 | 1 | 0.5 | 39 | 1.2 |
| Testis | 7 | 0.5 | 21 | 1.3 | 1 | 0.5 | 29 | 0.9 |
| Bone marrow + other | 12 | 0.9 | 41 | 2.5 | 8 | 4.3 | 61 | 1.9 |
| Other | 1 | 0.1 | 7 | 0.4 | 1 | 0.5 | 9 | 0.3 |
| Death in CCR | 10 | 0.7 | 13 | 0.8 | 20 | 10.6 | 43 | 1.4 |
| After chemotherapy | 10 | 0.7 | 10 | 0.6 | 6 | 3.2 | 26 | 0.8 |
| After stem cell transplantation | 0 | 3 | 0.2 | 14 | 7.4 | 17 | 0.6 | |
| Second malignant neoplasm† | 10 | 0.7 | 9 | 0.5 | 3 | 1.6 | 22 | 0.7 |
| CCR | 1267 | 94.1 | 1359 | 82.5 | 103 | 54.5 | 2729 | 85.7 |
| . | MRD-SR . | MRD-IR . | MRD-HR . | Total . | ||||
|---|---|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | No. . | % . | No. . | % . | |
| Total | 1348 | 42.3 | 1647 | 51.7 | 189 | 5.9 | 3184 | |
| Resistant* | 0 | 0 | 3 | 1.6 | 3 | 0.1 | ||
| Relapses | 61 | 4.5 | 266 | 16.2 | 60 | 31.7 | 387 | 12.1 |
| Bone marrow | 32 | 2.4 | 168 | 10.2 | 49 | 25.9 | 249 | 7.8 |
| Central nervous system | 9 | 0.6 | 29 | 1.8 | 1 | 0.5 | 39 | 1.2 |
| Testis | 7 | 0.5 | 21 | 1.3 | 1 | 0.5 | 29 | 0.9 |
| Bone marrow + other | 12 | 0.9 | 41 | 2.5 | 8 | 4.3 | 61 | 1.9 |
| Other | 1 | 0.1 | 7 | 0.4 | 1 | 0.5 | 9 | 0.3 |
| Death in CCR | 10 | 0.7 | 13 | 0.8 | 20 | 10.6 | 43 | 1.4 |
| After chemotherapy | 10 | 0.7 | 10 | 0.6 | 6 | 3.2 | 26 | 0.8 |
| After stem cell transplantation | 0 | 3 | 0.2 | 14 | 7.4 | 17 | 0.6 | |
| Second malignant neoplasm† | 10 | 0.7 | 9 | 0.5 | 3 | 1.6 | 22 | 0.7 |
| CCR | 1267 | 94.1 | 1359 | 82.5 | 103 | 54.5 | 2729 | 85.7 |
Only patients alive by TP2 are included in this cohort and consequently induction deaths in protocols IA and IB are not included.
ALL indicates acute lymphoblastic leukemia; MRD, minimal residual disease; SR, standard risk; IR, intermediate risk; HR, high risk; and CCR, continuous complete remission.
Resistant patients are those who did not achieve CR by the end of the third HR block of chemotherapy.
Acute myeloid leukemia (n = 9), myelodysplastic syndrome (n = 8), non-Hodgkin lymphoma (n = 1), glioblastoma (n = 1), brain tumor (n = 2), and other tumor (n = 1)